Hospital Infection Therapeutics Market at Significant CAGR of 2.4% from 2018 to 2030

Hospital Infection Therapeutics Market – Snapshot

Hospital-acquired infections are a highly prevalent adverse events in the health care industry. Presence of unhygienic conditions in and around hospitals along with improper sterilization techniques applied in these settings augments the prevalence of hospital-acquired infections in the low and middle income countries. The global hospital infection therapeutics market is characterized by increase in incidence of infections of resistance bacteria. The market is witnessing gradual rise in research and development activities to develop novel antibiotics, which are supported by government policies. Hence, the global hospital infection therapeutics market was valued at US$ 14.4 Bn in 2017 and is projected to expand at a significant CAGR of 2.4% from 2018 to 2026.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111987

ncrease in the geriatric population which is more prone to hospital-acquired infections, significant patient population in developing countries demanding proper treatment, and investments by public and private players for R&D on anti-infective drugs against resistant bacteria are the major factors driving the global hospital infection therapeutics market. However, surge in the incidence of treatment-emergent resistance, significant investment required due to high attrition rate in clinical trials, and changing reimbursement policies are resulting in limited pipeline drugs. This is likely to restrain the global hospital infection therapeutics market during the forecast period. Investment in R&D on non-antibiotic treatment options and partnerships for co-development and commercialization of anti-infective agents are expected to fuel the growth of the global hospital infection therapeutics market.

In terms of therapeutics, the global hospital infection therapeutics market has been classified into anti-bacterial drugs, anti-fungal drugs, anti-viral drugs, and others. The others segment comprises drug classes such as anti-parasitic drugs. The anti-bacterial drugs segment has been divided into cell wall synthesis inhibitors, protein synthesis inhibitors, and others. The cell wall synthesis inhibitors sub-segment comprises cephalosporins, carbapenems, vancomycin, and others. The protein synthesis inhibitors sub-segment comprises aminoglycosides, linezolid, tigecycline, and others. The anti-fungal drugs segment has been categorized into Caspofungin, Amphotericin B, and others. The others sub-segment includes Triazoles, fluconazole, voriconazole, and others. The anti-bacterial drugs segment is projected to dominate the market during the forecast period owing to an increase in initiatives such as the Global Action Plan on Antimicrobial Resistance by WHO and Drive AB by Innovative Medicines Initiative, and presence of key companies such as Merck & Co., Inc. and Pfizer, Inc. engaged in the manufacture of anti-bacterial drugs. These initiatives are aimed at increasing research and development activities to overcome drug resistance. The relatively stable growth rate of the segment is attributed to increase in antibiotic resistance of bacteria and limited pipeline drug candidates. The anti-viral drugs segment is anticipated to register above average growth rate owing to rise in the prevalence of severe bloodstream infections and increase in focus on research and development to overcome the risk of virus structural mutations. Based on infection, the market has been divided into hospital acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections, and other hospital infections. The hospital acquired pneumonia segment is likely to dominate the market during the forecast period with above average growth rate, followed by surgical site infections, due to increase in incidence rate of respiratory infections among the geriatric population, comparatively above average cost of therapy, and prevalence of multidrug-resistant micro-organisms in ICU units.

View full report@ https://qyresearchmedical.com/report/hospital-infection-therapeutics-market-therapeutics-anti-bacterial-drugs-anti-fungal-drugs-anti-viral-drugs-infection-hospital-acquired-pneumonia-urinary-tract-infections-gastrointestinal-disorders-bloods-018-2030/111987

In terms of region, the global hospital infection therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe accounted for major share of 39% of the global market in terms of revenue in 2017. North America was another major market for hospital infection therapeutics in 2017. Relatively high cost of treatment compared to that in emerging countries, developed health care infrastructure, and larger reimbursement coverage which provides assured investment return for new market entrants contribute to the significant share of the two regions. However, high growth rate of the pharmaceutical industry in India and China and investment by global investors in China for development of novel treatment approaches for hospital-acquired infections are expected to propel the hospital infection therapeutics market in Asia Pacific.

Major players operating in the global hospital infection therapeutics market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Allergan plc, Sanofi S.A., Gilead Sciences, Inc., Basilea Pharmaceutica Ltd., and Bristol-Myers Squibb Company.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111987/2900

The global hospital infection therapeutics market has been segmented as follows:

Therapeutics

  • Anti-bacterial Drugs
  • Anti-fungal Drugs
  • Anti-viral Drugs
  • Others

Infection

  • Hospital Acquired Pneumonia
  • Urinary Tract Infections
  • Gastrointestinal Disorders
  • Bloodstream Infections
  • Surgical Site Infections
  • Other Hospital Infections

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Israel
  • Rest of Middle East & Africa

TABLE OF CONTENT

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hospital Infection Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Therapeutics Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hospital Infection Therapeutics Market Analysis and Forecast, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1.Regulatory Scenario by Region/globally
5.2.Pipeline Analysis
5.3.Reimbursement Scenario by Region/globally
5.4.Disease Prevalence & Incidence Rate globally with key countries
5.5.Healthcare Industry Overview
5.6.Value Chain Analysis

6. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Therapeutics
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Forecast, by Therapeutics, 2016–2026
6.3.1. Antibacterial Drugs
6.3.1.1. Cell Wall Synthesis Inhibitors
6.3.1.2. Protein Synthesis Inhibitors
6.3.1.3. Others
6.3.2. Antifungal Drugs
6.3.2.1. Caspofungin
6.3.2.2. Amphotericin B
6.3.2.3. Others
6.3.3. Antiviral Drugs
6.3.4. Others
6.4. Market Attractiveness, by Therapeutics

7. Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Infection
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Forecast, by Infection, 2016–2026
7.3.1. Hospital Acquired Pneumonia
7.3.2. Urinary Tract Infections
7.3.3. Gastrointestinal Disorders
7.3.4. Bloodstream Infections
7.3.5. Surgical Site Infections
7.3.6. Other Hospital Infections
7.4. Market Attractiveness, by Infection

8. Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region

9. North America Hospital Infection Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Forecast, by Therapeutics, 2016–2026
9.2.1. Antibacterial Drugs
9.2.1.1. Cell Wall Synthesis Inhibitors
9.2.1.2. Protein Synthesis Inhibitors
9.2.1.3. Others
9.2.2. Antifungal Drugs
9.2.2.1. Caspofungin
9.2.2.2. Amphotericin B
9.2.2.3. Others
9.2.3. Antiviral Drugs
9.2.4. Others
9.3. Market Forecast, by Infection, 2016–2026
9.3.1. Hospital Acquired Pneumonia
9.3.2. Urinary Tract Infections
9.3.3. Gastrointestinal Disorders
9.3.4. Bloodstream Infections
9.3.5. Surgical Site Infections
9.3.6. Other Hospital Infections
9.4. Market Forecast, by Country, 2016–2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Therapeutics
9.5.2. By Infection
9.5.3. By Country

10. Europe Hospital Infection Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Forecast, by Therapeutics, 2016–2026
10.2.1. Antibacterial Drugs
10.2.1.1. Cell Wall Synthesis Inhibitors
10.2.1.2. Protein Synthesis Inhibitors
10.2.1.3. Others
10.2.2. Antifungal Drugs
10.2.2.1. Caspofungin
10.2.2.2. Amphotericin B
10.2.2.3. Others
10.2.3. Antiviral Drugs
10.2.4. Others
10.3. Market Forecast, by Infection, 2016–2026
10.3.1. Hospital Acquired Pneumonia
10.3.2. Urinary Tract Infections
10.3.3. Gastrointestinal Disorders
10.3.4. Bloodstream Infections
10.3.5. Surgical Site Infections
10.3.6. Other Hospital Infections
10.4. Market Forecast, by Country/Sub-region, 2016–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Therapeutics
10.5.2. By Infection
10.5.3. By Country/Sub-region

11. Asia Pacific Hospital Infection Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Forecast, by Therapeutics, 2016–2026
11.2.1. Antibacterial Drugs
11.2.1.1. Cell Wall Synthesis Inhibitors
11.2.1.2. Protein Synthesis Inhibitors
11.2.1.3. Others
11.2.2. Antifungal Drugs
11.2.2.1. Caspofungin
11.2.2.2. Amphotericin B
11.2.2.3. Others
11.2.3. Antiviral Drugs
11.2.4. Others
11.3.Market Forecast, by Infection, 2016–2026
11.3.1. Hospital Acquired Pneumonia
11.3.2. Urinary Tract Infections
11.3.3. Gastrointestinal Disorders
11.3.4. Bloodstream Infections
11.3.5. Surgical Site Infections
11.3.6. Other Hospital Infections
11.4.Market Forecast, by Country/Sub-region, 2016–2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5.Market Attractiveness Analysis
11.5.1. By Therapeutics
11.5.2. By Infection
11.5.3. By Country/Sub-region

12. Latin America Hospital Infection Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Forecast, by Therapeutics, 2016–2026
12.2.1. Antibacterial Drugs
12.2.1.1. Cell Wall Synthesis Inhibitors
12.2.1.2. Protein Synthesis Inhibitors
12.2.1.3. Others
12.2.2. Antifungal Drugs
12.2.2.1. Caspofungin
12.2.2.2. Amphotericin B
12.2.2.3. Others
12.2.3. Antiviral Drugs
12.2.4. Others
12.3.Market Forecast, by Infection, 2016–2026
12.3.1. Hospital Acquired Pneumonia
12.3.2. Urinary Tract Infections
12.3.3. Gastrointestinal Disorders
12.3.4. Bloodstream Infections
12.3.5. Surgical Site Infections
12.3.6. Other Hospital Infections
12.4.Market Forecast, by Country/Sub-region, 2016–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5.Market Attractiveness Analysis
12.5.1. By Therapeutics
12.5.2. By Infection
12.5.3. By Country/Sub-region

13. Middle East & Africa Hospital Infection Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Forecast, by Therapeutics, 2016–2026
13.2.1. Antibacterial Drugs
13.2.1.1. Cell Wall Synthesis Inhibitors
13.2.1.2. Protein Synthesis Inhibitors
13.2.1.3. Others
13.2.2. Antifungal Drugs
13.2.2.1. Caspofungin
13.2.2.2. Amphotericin B
13.2.2.3. Others
13.2.3. Antiviral Drugs
13.2.4. Others
13.3.Market Forecast, by Infection, 2016–2026
13.3.1. Hospital Acquired Pneumonia
13.3.2. Urinary Tract Infections
13.3.3. Gastrointestinal Disorders
13.3.4. Bloodstream Infections
13.3.5. Surgical Site Infections
13.3.6. Other Hospital Infections
13.4.Market Forecast, by Country/Sub-region, 2016–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Israel
13.4.4. Rest of Middle East & Africa
13.5.Market Attractiveness Analysis
13.5.1. By Therapeutics
13.5.2. By Infection
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1.Market Player – Competition Matrix (By Tier and Size of companies)
14.2.Market Share Analysis By Company (2017)
14.3.Market Footprint Analysis
14.4. Competitive Business Strategies
14.5. Company Profiles
14.5.1. Allergan
14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.1.2. Product Portfolio
14.5.1.3. SWOT Analysis
14.5.1.4. Strategic Overview
14.5.1.5. Financial Overview
14.5.2. AstraZeneca
14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.2.2. Product Portfolio
14.5.2.3. SWOT Analysis
14.5.2.4. Strategic Overview
14.5.2.5. Financial Overview
14.5.3. Basilea Pharmaceutica Ltd.
14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.3.2. Product Portfolio
14.5.3.3. SWOT Analysis
14.5.3.4. Strategic Overview
14.5.3.5. Financial Overview
14.5.4. Bayer AG
14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.4.2. Product Portfolio
14.5.4.3. SWOT Analysis
14.5.4.4. Strategic Overview
14.5.4.5. Financial Overview
14.5.5. Bristol-Myers Squibb Company
14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.5.2. Product Portfolio
14.5.5.3. SWOT Analysis
14.5.5.4. Strategic Overview
14.5.5.5. Financial Overview
14.5.6. F. Hoffman-La Roche Ltd.
14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.6.2. Product Portfolio
14.5.6.3. SWOT Analysis
14.5.6.4. Strategic Overview
14.5.6.5. Financial Overview
14.5.7. GlaxoSmithKline plc.
14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.7.2. Product Portfolio
14.5.7.3. SWOT Analysis
14.5.7.4. Strategic Overview
14.5.7.5. Financial Overview
14.5.8. Johnson & Johnson Services, Inc.
14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.8.2. Product Portfolio
14.5.8.3. SWOT Analysis
14.5.8.4. Strategic Overview
14.5.8.5. Financial Overview
14.5.9. Merck & Co., Inc.
14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.9.2. Product Portfolio
14.5.9.3. SWOT Analysis
14.5.9.4. Strategic Overview
14.5.9.5. Financial Overview
14.5.10. Pfizer Inc.
14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.10.2. Product Portfolio
14.5.10.3. SWOT Analysis
14.5.10.4. Strategic Overview
14.5.10.5. Financial Overview
14.5.11. Sanofi
14.5.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.11.2. Product Portfolio
14.5.11.3. SWOT Analysis
14.5.11.4. Strategic Overview
14.5.11.5. Financial Overview

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111987/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi